Abstract:In recent years, the U.S. Food and Drug Administration (FDA) has approved Chimeric Antigen Receptor (CAR)-T cell therapy as a novel approach to treating hematological diseases, including multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukemia. Using the patient's genetically altered T-cells, this novel strategy precisely targets antigens linked to cancer. Even with the encouraging outcomes of using bi-specific chimeric antigen receptors to stop tumor antigen evasion, difficulties still arise, especially when dealing with solid tumors. There are several challenges because of the intricate interactions among many elements in the tumor microenvironment, such as immunosuppression, hypoxia, decreased T-cell infiltration, elevated reactive oxygen species, and the erratic nature of tumor-associated antigens. This study examines current efforts to find reliable tumor-associated antigens in an attempt to address issues impeding the efficacy of CAR-T treatment. The fundamental objective is to create CAR-T cells that are economical while being adapted to the distinct characteristics of the tumor microenvironment. By means of a comprehensive analysis of the course of the therapy, the study explores its potential therapeutic uses for a range of tumor types, including solid and hematological malignancies. This work not only sheds light on the enormous obstacles to obtaining precision medicine in cancer treatment, but it also advances our knowledge of the promise that the specific therapy has. The presented results open the door for future developments in the field and provide a nuanced viewpoint on the revolutionary role that the treatment has played in the contemporary cancer scene.

CAR-T cell therapy in advanced thyroid cancer: from basic to clinical

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Current progress in CAR-T cell therapy for tumor treatment

CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application

Prospects and challenges of immunotherapy for thyroid cancer

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer

Current Progress in CAR-T Cell Therapy for Solid Tumors

Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Current Clinical Application of the CAR-T Cell Therapy

Advances in CAR-T-cell therapy in T-cell malignancies

CAR-T in cancer therapeutics and updates

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)